ArticleCureus2025
Complete Response Following Multimodal Treatment of HER2-Positive Oligometastatic Apocrine Breast Carcinoma: A Report of a Rare Case and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apocrine carcinoma of the breast is a rare histologic subtype characterized by distinctive morphological and immunohistochemical features. Due to its infrequent occurrence, there is a paucity of specific management guidelines, with treatment generally following the protocols applied to more common breast cancer subtypes. Here, we report the case of a 54-year-old woman with HER2-positive apocrine breast carcinoma and a solitary bone metastasis in the L5 vertebra. She received neoadjuvant chemotherapy combined with dual anti-HER2 therapy (trastuzumab and pertuzumab), followed by a right mastectomy with axillary lymph node dissection, locoregional conformal radiotherapy, and stereotactic radiotherapy to the L5 lesion. The patient then underwent adjuvant maintenance targeted therapy. A complete response, both histological and metabolic, was achieved and has been sustained after two years of follow-up. This case underscores the value of a personalized, multimodal treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.